Research · Sep 3, 2026
[ONC] BeOne Medicines Thesis 2026: Tevimbra Global Launch Tests China Oncology Pivot
BeOne Medicines Ltd. (NASDAQ: ONC; previously BeiGene through October 2024) FY2025 revenue ~$5.3-5.8B (+50-60%) with adj. EPS ~$1.40-1.85 reflecting continued Tevimbra (tislelizumab; PD-1 inhibitor) ~$1.5-2B aggregate global revenue (~$1B+ China + ~$0.5-1B post-2024 US + EU + selected various global launch) plus continued Brukinsa (zanubrutinib; BTK inhibitor) ~$3.0-3.4B aggregate global revenue (~$2-2.4B+ US + EU + selected various global) plus selected post-October 2024 BeiGene → BeOne Medicines rebranding + selected continued post-2024 NASDAQ + Hong Kong + Shanghai Stock Exchange triple listing under continued co-founder + Chairman + CEO John Oyler (~14-year tenure since 2010 founding). Global biopharmaceutical company focused on oncology with operations across drug development + commercialization + selected various manufacturing in US + China + EU + selected various. Founded 2010 as BeiGene Ltd. in Beijing China by John Oyler + Xiaodong Wang (Nobel laureate) (~14-year heritage); selected post-2016 NASDAQ IPO (~$182M raised); selected post-2018 Hong Kong Stock Exchange listing IPO (~$903M raised); selected post-2021 Shanghai Stock Exchange STAR Market listing IPO (~$3.5B raised); selected post-November 2019 Brukinsa first FDA approval; selected post-March 2024 Tevimbra first FDA approval; selected post-October 2024 BeiGene → BeOne Medicines rebranding + ticker change BGNE → ONC. Headquartered in Cambridge Massachusetts US (selected post-October 2024 US HQ relocation; selected continued China + Switzerland operating sites); ~10,000+ employees globally with ~$5.3-5.8B revenue. Single primary product franchise structure: Brukinsa ~$3.0-3.4B + Tevimbra ~$1.5-2B + selected various oncology + R&D collaboration ~$0.8-1B. Brukinsa franchise leadership: ~$3.0-3.4B aggregate global revenue FY2025 (+30-40% YoY); leading BTK inhibitor globally; approved indications CLL + MCL + WM + MZL + selected various B-cell malignancies; ~50%+ aggregate US BTK new patient share; ~$5-7B+ peak sales potential. Tevimbra global launch: ~$1.5-2B aggregate global revenue FY2025; March 2024 first US FDA approval for ESCC; selected post-2024 EU EMA approval expansion; ~10+ active Tevimbra global pivotal trials covering lung + gastric + esophageal + selected various; ~$2-4B+ peak sales potential. BeiGene → BeOne Medicines rebranding: post-October 2024 brand transition + HQ relocation to Cambridge Massachusetts + selected continued China commercial + R&D + manufacturing operations + selected post-2024 China oncology pivot. Co-founder + Chairman + CEO John Oyler since 2010 founding (~14-year tenure); CFO Aaron Rosenberg. Capital structure: ~$2.5-3B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + R&D); ~$1.5-2B annual R&D spend; investment-grade B2/B credit rating. FY2026 thesis: Brukinsa global franchise leadership + Tevimbra global launch + post-October 2024 BeOne Medicines rebranding + FCF positive trajectory + selected post-2024 China oncology pivot. Risks: Brukinsa Imbruvica + Calquence + Jaypirca BTK competition, Tevimbra Keytruda + Opdivo PD-1 competition, China oncology pivot execution, R&D pipeline failures, USD/CNY currency volatility.